Publications by authors named "Traci Turner"

Claim this Profile
Z
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial.
Frederick J Raal, Jean Bergeron, Daniel Gaudet, Robert S Rosenson, David R Sullivan, Traci Turner

Lancet Diabetes Endocrinol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and effectiveness of evinacumab in people with homozygous familial hypercholesterolemia: a plain language summary.
Daniel Gaudet, Susanne Greber-Platzer, Laurens F Reeskamp, Gabriella Iannuzzo, Robert S Rosenson, Traci Turner

Future Cardiol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.
Frederick J Raal, Vimal Mehta, Meral Kayikcioglu, Dirk Blom, Preeti Gupta, Traci Turner

Lancet Diabetes Endocrinol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy.
Daniel Gaudet, Susanne Greber-Platzer, Laurens F Reeskamp, Gabriella Iannuzzo, Robert S Rosenson, Traci Turner

Eur Heart J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition.
Seth S Martin, Marc Ditmarsch, Mark Simmons, Nicholas Alp, Traci Turner

Eur Heart J Cardiovasc Pharmacother· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.
Steven E Nissen, Kathy Wolski, Craig Balog, Daniel I Swerdlow, Alison C Scrimgeour, Traci Turner

JAMA· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting PCSK9 inhibitors to those who will benefit most.
Traci A Turner, Evan A Stein

Lancet Diabetes Endocrinol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program.
Frederick J Raal, El Mustapha Bahassi, Belinda Stevens, Traci A Turner, Evan A Stein

Arterioscler Thromb Vasc Biol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Frederick J Raal, David Kallend, Kausik K Ray, Traci Turner, Wolfgang Koenig

N Engl J Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response by Kusters et al to Letter Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)".
D Meeike Kusters, Marjet J A M Braamskamp, Gisle Langslet, Brian W McCrindle, David Cassiman, Traci Turner

Circulation· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of buprenorphine/naloxone dose and use of sedating supportive medication on treatment outcomes in veterans with opioid use disorder.
Amber Kapuganti, Traci Turner, Christopher J Thomas

Ment Health Clin· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label).
Marjet J A M Braamskamp, Gisle Langslet, Brian W McCrindle, David Cassiman, Gordon A Francis, Traci Turner

Circulation· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?
Evan A Stein, Traci A Turner

Expert Rev Cardiovasc Ther· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
Kausik K Ray, Ulf Landmesser, Lawrence A Leiter, David Kallend, Robert Dufour, Traci Turner

N Engl J Med· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study.
Marjet J A M Braamskamp, Gisle Langslet, Brian W McCrindle, David Cassiman, Gordon A Francis, Traci Turner

J Clin Lipidol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes.
Traci Turner, Evan A Stein

Clin Ther· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Frederick J Raal, Evan A Stein, Robert Dufour, Traci Turner, Fernando Civeira

Lancet· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis